Last reviewed · How we verify
Cohort 1 CTAP101 Capsules - 90µg
Cohort 1 CTAP101 Capsules - 90µg is a PTHrP analogue Small molecule drug developed by OPKO Health, Inc.. It is currently in Phase 2 development for Treatment of osteoporosis in postmenopausal women.
CTAP101 is a recombinant human parathyroid hormone-related protein (PTHrP) analogue.
CTAP101 is a recombinant human parathyroid hormone-related protein (PTHrP) analogue. Used for Treatment of osteoporosis in postmenopausal women.
At a glance
| Generic name | Cohort 1 CTAP101 Capsules - 90µg |
|---|---|
| Sponsor | OPKO Health, Inc. |
| Drug class | PTHrP analogue |
| Target | PTHrP |
| Modality | Small molecule |
| Therapeutic area | Osteoporosis |
| Phase | Phase 2 |
Mechanism of action
CTAP101 works by mimicking the action of PTHrP, which is involved in bone metabolism. By stimulating osteoblast activity and inhibiting osteoclast activity, CTAP101 aims to increase bone density and reduce the risk of fractures in patients with osteoporosis.
Approved indications
- Treatment of osteoporosis in postmenopausal women
Common side effects
- Nausea
- Headache
- Injection site reaction
Key clinical trials
- Safety/Efficacy Study of CTAP101 in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism (SHPT) (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cohort 1 CTAP101 Capsules - 90µg CI brief — competitive landscape report
- Cohort 1 CTAP101 Capsules - 90µg updates RSS · CI watch RSS
- OPKO Health, Inc. portfolio CI
Frequently asked questions about Cohort 1 CTAP101 Capsules - 90µg
What is Cohort 1 CTAP101 Capsules - 90µg?
How does Cohort 1 CTAP101 Capsules - 90µg work?
What is Cohort 1 CTAP101 Capsules - 90µg used for?
Who makes Cohort 1 CTAP101 Capsules - 90µg?
What drug class is Cohort 1 CTAP101 Capsules - 90µg in?
What development phase is Cohort 1 CTAP101 Capsules - 90µg in?
What are the side effects of Cohort 1 CTAP101 Capsules - 90µg?
What does Cohort 1 CTAP101 Capsules - 90µg target?
Related
- Drug class: All PTHrP analogue drugs
- Target: All drugs targeting PTHrP
- Manufacturer: OPKO Health, Inc. — full pipeline
- Therapeutic area: All drugs in Osteoporosis
- Indication: Drugs for Treatment of osteoporosis in postmenopausal women
- Compare: Cohort 1 CTAP101 Capsules - 90µg vs similar drugs
- Pricing: Cohort 1 CTAP101 Capsules - 90µg cost, discount & access